Novartis, a Swiss multinational pharmaceutical company announced that soon it would submit two drug applications to U.S Food Drug and Administration. The new drugs would fight against chronic obstructive pulmonary disease (COPD).

The drug manufacturer filed the request for the two drugs at the end of the 2014. The drugs, QVA149 and NVA237 successfully passed the third test. It showed considerable improvement in the functioning of lungs.

The two medicines have already touched the markets all around the globe except the United States. Hence, the company has now completed the submission process of the two drugs in the United States.

The World Health Organization says that drug makers are trying really hard to introduce new respiratory treatment. The latest report shows that after every 10 seconds a person dies due to Chronic Obstructive Pulmonary Disease (COPD). The disease is expected to become the third largest death factor till 2020.